Navigation Links
Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
Date:5/28/2009

dosimetry trial is underway and patient follow-up in that trial also is continuing. Data from this trial continues to support the superior targeting properties of Cotara and the resulting accumulation of high doses of radiation specifically in the tumor.

"We are encouraged at the continuing progress in the Cotara clinical program, with screening for the anticipated final patient in the dosing and dosimetry trial now underway, more than half of the planned GBM patients enrolled in the Phase II trial, and acceptance of our oral presentation at the upcoming Society of Nuclear Medicine Annual Meeting," said Steven W. King, president and CEO of Peregrine. "Patients have tolerated the Cotara regimen well and we continue to see longer-term survivors among the treated patients, consistent with our experience in previous Cotara clinical studies."

Overall, Cotara has been administered to a total of more than 115 patients with brain, colon or liver cancer. Promising data from these studies support Cotara's ability to specifically target solid tumors and its anti-tumor activity, as well as its acceptable safety profile.

Mr. King added, "We continue to actively explore partnering opportunities and options for expanding the accessibility of Cotara to GBM patients in the U.S. and other territories, to ensure continued development of this drug candidate that we believe may offer a positive treatment option for patients with this devastating disease."

The primary objective of the open label, multi-center Phase II trial is to confirm the maximum tolerated dose of Cotara in GBM patients at first relapse. Secondary objectives include estimates of overall patient survival, progression free survival and the proportion of patients alive at six months. Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), a technique that delivers the agent to the tumor with great
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
7. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
8. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
9. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
10. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
11. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 28, 2014 Bleeding gums are not to ... flossing, according to the prosthodontists at the Anacapa Dental Art ... serious medical conditions, Dr. Saj Jivraj and Dr. Mamaly Reshad ... are not properly cleaning your teeth all the way down ... bleed easily,” Dr. Jivraj said. , Despite their reputations for ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 In the ... and private practices struggle with: How can the overall ... new multi-year study of the healthcare industry tackles this ... correlation between employee job satisfaction and the quality of ... can be found in “ Organizational Factors related to ...
(Date:8/28/2014)... AMTC graduate, rising star and The Voice Season ... the Top 10 finalists for Pepsi’s Southern Original . He’s ... for his mentor and coach from The Voice and country music ... slot on Thursday, August 28th at 9:00 pm at Tootsie’s at ... will perform at the Gulf Coast Jam main stage on Sunday, ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Top ... many web hosting companies and announces Bluehost, HostMonster ... recommended suppliers for the webmasters worldwide who want ... rates. , As the world’s most popular server-side ... and many other general-purpose programs. It is now ...
(Date:8/28/2014)... August 28, 2014 Alpine, NJ resident ... of his team, Zebras In Tiaras, to benefit the ... be held October 26, 2014 in Foley Square, New ... immunodeficiency community. Primary immunodeficiency diseases (PI) are a group ... which part of the body’s immune system is missing ...
Breaking Medicine News(10 mins):Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 2Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 3Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 4Health News:Elite Oxnard, Calif., Dentists Offer 4 Tips for Protecting Children’s Gums 5Health News:New Healthcare Study Explores Strategies for Improving Patient Care 2Health News:New Healthcare Study Explores Strategies for Improving Patient Care 3Health News:New Healthcare Study Explores Strategies for Improving Patient Care 4Health News:Rising Star Brandon Chase Named Finalist in Pepsi Southern Original Contest 2
... officials say company distributed ,adulterated, peanut butter products in ... -- The Georgia facility that produced the peanut butter ... in the past distributed questionable peanut butter product, U.S. ... 2008, Peanut Corporation of America, which owns the now-closed ...
... for Patient-Provider Decision MakingFurther Action Needed to Ensure ... Senate today improved on a comparative effectiveness research ... $1.1 billion dollar research effort on clinical effectiveness," ... of the National Alliance for Hispanic Health, the ...
... Ringling Bros.(R) Conservation and Breeding ProgramVIENNA, Va., Jan. 27 ... Elephant Conservation (R) proudly announces the ... twenty-second birth in what has proven to be the most ... importantly, this is the first calf in the Ringling ...
... Healthcare Realty,Trust Incorporated (NYSE: HR ) ... the market closes, it will report results for the ... February 24, 2009, at 9:00 a.m. Central Time, Healthcare ... results, quarterly activities,general operations of the Company and industry ...
... has completed a new study on uric acid and C8 and ... increased uric acid is associated with higher levels of C8 and ... can cause an increase in uric acid.The Science Panel team recently ... (also known as PFOA) and C8S (also known as PFOS) in ...
... St. Jude Children,s Research Hospital and the Children,s Oncology ... leukemia (ALL) scores of inherited genetic variations that clinicians ... more effective chemotherapy for this cancer. ... rates for ALL exceed 80 percent, patient responses vary ...
Cached Medicine News:Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 2Health News:Salmonella Outbreak Plant Shipped Dubious Product Before: U.S. Health Officials 3Health News:Statement on Comparative Effectiveness Research Under Senate Appropriations Committee Stimulus Bill 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 2Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 3Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 4Health News:Ringling Bros. and Barnum & Bailey(R) Proudly Announces Its First Elephant Calf Born From Artificial Insemination 5Health News:Healthcare Realty Trust Announces Fourth Quarter Earnings Release Date and Conference Call 2Health News:C8 Science Panel Completes Uric Acid Study 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 2Health News:St. Jude finds more than 100 gene variations linked with response to leukemia treatment 3
(Date:8/27/2014)... , Aug. 27, 2014 Sihuan Pharmaceutical ... the "Company"), a leading pharmaceutical company with the ... China,s prescription drug market, today ... and its subsidiaries (collectively the "Group") for the ... Financial HighlightsFor the Six months ended ...
(Date:8/27/2014)... , Aug. 27, 2014  Columbia Laboratories, Inc. ... a provider of pharmaceutical development, clinical trial manufacturing, and ... today announced that it will participate at the upcoming ... Conference, to be held in New York ... at 11:15am on September 9, 2014 at the New ...
(Date:8/27/2014)... "Fatty Liver Disease Global Clinical Trials Review, H2, 2014″ ... scenario. This report provides elemental information and data relating ... . It includes an overview of the trial numbers ... trial conduction across the globe. The databook offers a ... trial status, prominence of the sponsors and also provides ...
Breaking Medicine Technology:Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 2Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 3Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 4Fatty Liver Disease Therapeutics Clinical Trials Market Review 2014 Analysis Report Available at MarketOptimizer.org 5
... Medical Systems Ltd. (NASDAQ: DHRM) ("Dehaier" or ... assembly, marketing and sale of medical devices and ... plans to release its financial results for the ... 31, 2011 on Monday, March 19, 2012, after the stock ...
... Timothy C. Tyson, Aptuit Chairman, announced that effective immediately, ... Operating Officer of Aptuit LLC. Following the recent sale ... has been promoted from his previous position at Aptuit ... Needleman is responsible for all day-to-day operations of the ...
Cached Medicine Technology:Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 2Dehaier Medical Systems Schedules 2011 Fourth Quarter and Full Year Financial Results and Conference Call 3Aptuit LLC Names Stuart E. Needleman as President and Chief Operating Officer 2
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... the ease and comfort you've come to expect ... in clinical trials agreed that the BD Lancet ... settings allow you to choose the best lancet ... lancets, the device also helps eliminate the "vibrations" ...
... StaRRsed-III is a system that measures ... samples. This rate may be relevant ... The sedimentation rate is measured in ... typically used in high-volume settings such ...
Medicine Products: